Smoking Cessation Drug Suspected in 30 Suicides in Canada

From a Report in the Vancouver Sun

Champix is suspected of playing a major role in the deaths of 44 patients — 30 of them by suicide — since the popular stop-smoking drug was approved in Canada in 2007, a Vancouver Sun investigation has found.

The Pfizer drug has also been linked to more than 1,300 incidents of suicide attempts or thoughts, depression, and aggression/anger across the country in the past seven years.

The drug is the most popular of those offered by B.C.’s quit smoking program, which traditionally sees a jump in participation every January as people renew new year’s resolutions to butt out.

Numbers on the deaths and other side-effects come from a Health Canada database where doctors, pharmacists and drug companies report bad side-effects experienced by patients taking pharmaceuticals.

But Health Canada admits on its website that side-effects are under-reported, and experts say the database could represent as little as one per cent of the patients who suffer complications.

“A small proportion of the adverse reactions that have occurred on this drug in Canada would be in the adverse reaction database. Essentially it is spontaneous, voluntary reporting,” said Barbara Mintzes, a pharmaceutical drug expert at the University of B.C.

Even the incomplete numbers, though, are a concern, she said. When someone taking an anti-depressant attempts suicide, it’s initially not clear whether that’s caused by the pre-existing depression or the drug; but in the case of Champix, people are taking the drug to stop smoking — not for a mental health condition.

“You are looking at a lot of deaths, suicides and attempted suicides, and suicidal ideation in a population that you would have no reason to think would be otherwise at high risk of suicide,” said Mintzes, an associate professor in the Faculty of Medicine’s School of Population and Public Health.

The Sun downloaded data from the Health Canada site for Champix and Zyban, the two drugs covered by Pharmacare as part of the province’s Smoking Cessation program.

Champix is the subject of a class-action lawsuit, which more than 200 Canadians have joined, alleging psychiatric side-effects. One of the plaintiffs is the mother of a B.C. woman who killed herself while she was on the drug.

In recent years, Champix has been slapped with the toughest safety warnings in the U.S. and Canada, and France stopped covering the drug through its public Pharmacare system.

Much more information at the lihnk